Andreas Argyrides
Stock Analyst at Chardan Capital
(4.28)
# 1,406
Out of 4,604 analysts
375
Total ratings
44.1%
Success rate
9.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Maintained: Buy | $10 → $13 | $3.78 | +243.92% | 2 | Jul 6, 2026 | |
| EYPT EyePoint | Maintained: Buy | $65 | $12.25 | +430.61% | 1 | Jul 1, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $3.76 | +113.05% | 20 | Jun 25, 2026 | |
| SVRA Savara | Maintained: Buy | $11 | $5.51 | +99.64% | 6 | Jun 3, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $40 | $26.17 | +52.85% | 9 | May 21, 2026 | |
| UTHR United Therapeutics | Rated: Hold | n/a | $519.01 | - | 19 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $4.10 | - | 8 | May 11, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $12.69 | - | 3 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $89.12 | - | 17 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $0.1777 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $119.23 | - | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.00 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.55 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.36 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.10 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $98 | $61.29 | +59.90% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $38.24 | +62.13% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $13.02 | +222.58% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.97 | +356.85% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $7 | $1.77 | +295.48% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $15.93 | +132.27% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $0.701 | +106,890.01% | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.78 | n/a | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.022 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $11.53 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $105 | $21.73 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.0994 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $12.07 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $10.50 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $24.87 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $59.91 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $14.01 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $244.20 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.741 | n/a | 6 | Aug 25, 2022 |
Opus Genetics
Jul 6, 2026
Maintained: Buy
Price Target: $10 → $13
Current: $3.78
Upside: +243.92%
EyePoint
Jul 1, 2026
Maintained: Buy
Price Target: $65
Current: $12.25
Upside: +430.61%
Aquestive Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $8
Current: $3.76
Upside: +113.05%
Savara
Jun 3, 2026
Maintained: Buy
Price Target: $11
Current: $5.51
Upside: +99.64%
Dyne Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $40
Current: $26.17
Upside: +52.85%
United Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $519.01
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $4.10
Upside: -
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $12.69
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $89.12
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $0.1777
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $119.23
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.00
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $17.55
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $5.36
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $4.10
Upside: -
Apr 24, 2026
Maintained: Buy
Price Target: $105 → $98
Current: $61.29
Upside: +59.90%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $38.24
Upside: +62.13%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $13.02
Upside: +222.58%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.97
Upside: +356.85%
Nov 11, 2025
Maintained: Buy
Price Target: $3 → $7
Current: $1.77
Upside: +295.48%
Oct 9, 2025
Maintained: Buy
Price Target: $37
Current: $15.93
Upside: +132.27%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $0.701
Upside: +106,890.01%
Jul 17, 2025
Rated: Hold
Price Target: n/a
Current: $0.78
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.022
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $11.53
Upside: n/a
Aug 13, 2024
Maintained: Hold
Price Target: $105
Current: $21.73
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.0994
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $12.07
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $10.50
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $24.87
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $59.91
Upside: n/a
Feb 22, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $14.01
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $244.20
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $0.741
Upside: n/a